A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease
This study will evaluate the efficacy, safety, and effect on quality of life of oral ibandronate (Bondronat) in participants with breast cancer and metastatic bone disease. The anticipated time on study treatment is 25 weeks, and the target sample size is 50 individuals.
Pain; Bone Neoplasms; Neoplasm Metastasis
DRUG: Ibandronate
Cumulative incidence of skeletal events according to Skeletal Morbidity Period Rate (SMPR), Up to 25 weeks
Incidence of bone pain according to participant questionnaire, Up to 25 weeks|Analgesic consumption according to participant questionnaire, Up to 25 weeks|Change in serum pyridinoline cross-linked carboxyterminal telopeptide of collagen type I (ICTP), Up to 25 weeks|Short Form 36 (SF-36) score, Up to 25 weeks|Incidence of adverse events (AEs), Up to approximately 7 months
This study will evaluate the efficacy, safety, and effect on quality of life of oral ibandronate (Bondronat) in participants with breast cancer and metastatic bone disease. The anticipated time on study treatment is 25 weeks, and the target sample size is 50 individuals.